Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOIST‐WHF in perspective-Reference-Cited by-同舟云学术

Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOIST‐WHF in perspective

Published:2020-12 Issue:6 Volume:7 Page:3261-3267
ISSN:2055-5822
Container-title:ESC Heart Failure
language:en
Short-container-title:ESC Heart Failure

Author:

Verma Subodh¹,Anker Stefan D.²,Butler Javed³,Bhatt Deepak L.⁴

Affiliation:

1. Division of Cardiac Surgery, St. Michael's Hospital University of Toronto 30 Bond Street Toronto ON M5B 1W8 Canada

2. Department of Cardiology (CVK) and Berlin Institute of Health Centre for Regenerative Therapies (BCRT) Charité‐Universitätsmedizin Berlin, and the German Centre for Cardiovascular Research (DZHK) Partner Site Berlin Germany

3. Department of Medicine University of Mississippi School of Medicine Jackson MI USA

4. Brigham and Women's Hospital Heart and Vascular Center Harvard Medical School Boston MA USA

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ehf2.13148

Reference56 articles.

1. Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction

2. The vulnerable phase after hospitalization for heart failure

3. Acute heart failure: from pathophysiology to optimal treatment

4. Timely Management of New-Onset Heart Failure

5. Recognizing the Significance of Outpatient Worsening Heart Failure

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing the Effect of Sodium-Glucose Cotransporter 2 Inhibitor (SGLT2i) on Outcomes in Patients With Acute Myocardial Infarction: A Systematic Review and Meta-Analysis;Cureus;2024-06-23

2. The Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors on Cardiovascular Outcomes and All-Cause Mortality in Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis;Cureus;2024-04-11

3. Time to clinical benefit with sotagliflozin in patients with type 2 diabetes and chronic kidney disease: Insights from the SCORED randomized trial;European Journal of Heart Failure;2024-04

4. Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF;JACC: Heart Failure;2024-01

5. Heterogeneity in cardiorenal protection by Sodium glucose cotransporter 2 inhibitors in heart failure across the ejection fraction strata: Systematic review and meta-analysis;World Journal of Nephrology;2023-12-25